Michelle Petri
YOU?
Author Swipe
View article: Correction: A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM
Correction: A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM Open
View article: Characteristics, treatment patterns and healthcare resource use of Finnish men with prostate cancer
Characteristics, treatment patterns and healthcare resource use of Finnish men with prostate cancer Open
Objectives To characterize patients diagnosed with prostate cancer (PC) in Finland in 2015–2019 and to follow‐up the treatment patterns and healthcare resource use for patients with nonmetastatic PC (nmPC) and metastatic PC (mPC) until the…
View article: A population-scale atlas of blood and tissue in lupus nephritis
A population-scale atlas of blood and tissue in lupus nephritis Open
Lupus nephritis (LN), a severe manifestation of Systemic lupus erythematosus (SLE), is a heterogeneous disease driven by diverse immune and tissue cell types. Current treatments of LN are non-specific, increase risk of infection, and have …
View article: Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE Open
View article: Development of the 2023 <scp>ACR</scp>/<scp>EULAR</scp> Antiphospholipid Syndrome Classification Criteria, Phase <scp>III</scp>‐C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions
Development of the 2023 <span>ACR</span>/<span>EULAR</span> Antiphospholipid Syndrome Classification Criteria, Phase <span>III</span>‐C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions Open
Objective The 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification criteria aim to identify patients with high likelihood of APS for research. Phases I/II of our four‐phase methodological approach resulted in 27 candidate criteria…
View article: Towards a minimal core dataset for systemic lupus erythematosus studies
Towards a minimal core dataset for systemic lupus erythematosus studies Open
Objective SLE is a complex, heterogenous autoimmune disease. SLE researchers do not always collect the same data, making comparative studies difficult. We aimed to ascertain what variables SLE clinical researchers commonly collect for SLE …
View article: OP0201 ACHIEVEMENT OF LOW DISEASE ACTIVITY AND REMISSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH DAPIROLIZUMAB PEGOL: 48-WEEK RESULTS FROM A PHASE 3 TRIAL
OP0201 ACHIEVEMENT OF LOW DISEASE ACTIVITY AND REMISSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH DAPIROLIZUMAB PEGOL: 48-WEEK RESULTS FROM A PHASE 3 TRIAL Open
View article: ABS0316 EFFICACY ACROSS BASELINE CHARACTERISTIC SUBGROUPS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH UPADACITINIB: RESULTS FROM SLEek, A PHASE 2 RANDOMIZED CLINICAL TRIAL
ABS0316 EFFICACY ACROSS BASELINE CHARACTERISTIC SUBGROUPS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH UPADACITINIB: RESULTS FROM SLEek, A PHASE 2 RANDOMIZED CLINICAL TRIAL Open
View article: ABS0077 MOLECULARLY DIVERSE PR3+ CELLS CHARACTERIZE LUPUS NEPHRITIS: A SPATIALLY RESOLVED MULTI-OMICS APPROACH
ABS0077 MOLECULARLY DIVERSE PR3+ CELLS CHARACTERIZE LUPUS NEPHRITIS: A SPATIALLY RESOLVED MULTI-OMICS APPROACH Open
View article: POS0734 DAPIROLIZUMAB PEGOL DEMONSTRATED SIGNIFICANT IMPROVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY: EFFICACY AND SAFETY RESULTS OF A PHASE 3 TRIAL
POS0734 DAPIROLIZUMAB PEGOL DEMONSTRATED SIGNIFICANT IMPROVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY: EFFICACY AND SAFETY RESULTS OF A PHASE 3 TRIAL Open
View article: POS0317 THE IMMUNE MAP OF LUPUS NEPHRITIS: A SPATIALLY-RESOLVED KIDNEY PROTEOMIC APPROACH
POS0317 THE IMMUNE MAP OF LUPUS NEPHRITIS: A SPATIALLY-RESOLVED KIDNEY PROTEOMIC APPROACH Open
View article: POS0200 TYPE I INTERFERON ACTIVITY IN PERSISTENTLY ANTIPHOSPHOLIPID ANTIBODY-POSITIVE PATIENTS WITH OR WITHOUT LUPUS: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) CLINICAL DATABASE AND REPOSITORY (“REGISTRY”)
POS0200 TYPE I INTERFERON ACTIVITY IN PERSISTENTLY ANTIPHOSPHOLIPID ANTIBODY-POSITIVE PATIENTS WITH OR WITHOUT LUPUS: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) CLINICAL DATABASE AND REPOSITORY (“REGISTRY”) Open
View article: NONINVASIVE HIGH-THROUGHPUT SERUM PROTEOMICS FOR DISTINGUISHING SUBTYPES OF LUPUS NEPHRITIS
NONINVASIVE HIGH-THROUGHPUT SERUM PROTEOMICS FOR DISTINGUISHING SUBTYPES OF LUPUS NEPHRITIS Open
PT006 / #521 Topic: AS15 - Lupus Nephritis-Clinical POSTER TOUR 02: RECENT INSIGHTS ON THE PATHOGENESIS OF LUPUS NEPHRITIS 23-05-2025 10:00 AM - 10:40 AM Background/Purpose Lupus nephritis (LN) treatment decisions are commonly guided by hi…
View article: PROTEOMIC ANALYSIS OF SERUM OVER TIME TO FORECAST TREATMENT RESPONSE IN LUPUS NEPHRITIS
PROTEOMIC ANALYSIS OF SERUM OVER TIME TO FORECAST TREATMENT RESPONSE IN LUPUS NEPHRITIS Open
O061 / #515 Topic: AS15 - Lupus Nephritis-Clinical ABSTRACT CONCURRENT SESSION 10: INTEGRATING PROTEOMIC & TRANSCRIPTOMICS IN SLE 24-05-2025 10:40 AM - 11:40 AM Background/Purpose Lupus nephritis (LN) can cause severe complications and ear…
View article: CLINICAL AND HISTOLOGICAL PREDICTORS OF RENAL FUNCTION LOSS IN LUPUS NEPHRITIS: RESULTS FROM THE ACCELERATING MEDICINES PARTNERSHIP IN RA/SLE NETWORK
CLINICAL AND HISTOLOGICAL PREDICTORS OF RENAL FUNCTION LOSS IN LUPUS NEPHRITIS: RESULTS FROM THE ACCELERATING MEDICINES PARTNERSHIP IN RA/SLE NETWORK Open
O040 / #227 Topic: AS15 - Lupus Nephritis-Clinical ABSTRACT CONCURRENT SESSION 06: LUPUS NEPHRITIS – CLINICAL OUTCOMES, PREDICTION AND THERAPY 23-05-2025 1:40 PM - 2:40 PM Background/Purpose Kidney survival is the ultimate outcome in lupus…
View article: INTERVAL-CENSORED OUTCOMES AND FLARE RISK AFTER HYDROXYCHLOROQUINE TAPERING/CESSATION: SENSITIVITY ANALYSES OF SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) INCEPTION COHORT DATA
INTERVAL-CENSORED OUTCOMES AND FLARE RISK AFTER HYDROXYCHLOROQUINE TAPERING/CESSATION: SENSITIVITY ANALYSES OF SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) INCEPTION COHORT DATA Open
O052 / #245 Topic: AS24 - SLE-Treatment ABSTRACT CONCURRENT SESSION 09: SLE THERAPY – REVISITING OLD DRUGS AND UNLOCKING HIDDEN POTENTIAL OF NEW MEDICATIONS 24-05-2025 10:40 AM - 11:40 AM Background/Purpose We previously evaluated hydroxyc…
View article: RHEUMATOLOGY DIAGNOSTICS UTILIZING ARTIFICIAL INTELLIGENCE FOR ANA PATTERN IDENTIFICATION AND TITRE QUANTIFICATION
RHEUMATOLOGY DIAGNOSTICS UTILIZING ARTIFICIAL INTELLIGENCE FOR ANA PATTERN IDENTIFICATION AND TITRE QUANTIFICATION Open
PT012 / #274 Topic: AS23 - SLE-Diagnosis, Manifestations, & Outcomes POSTER TOUR 03: RECENT ADVANCEMENTS IN SLE CLINICAL OUTCOMES AND THERAPY 23-05-2025 10:00 AM - 10:40 AM Background/Purpose Antinuclear antibody (ANA) immunofluorescence (…
View article: DESIGN OF A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MK-6194, AN INTERLEUKIN-2 MUTEIN, IN ADULT PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
DESIGN OF A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MK-6194, AN INTERLEUKIN-2 MUTEIN, IN ADULT PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Open
PV264 / #825 Poster Topic: AS24 - SLE-Treatment Background/Purpose Regulatory T cell (Treg) dysfunction is a key feature of systemic lupus erythematosus (SLE). Preliminary studies expanding Tregs in patients with SLE using low-dose interle…
View article: DIRECT AND INDIRECT COSTS ASSOCIATED WITH DAMAGE ACCRUAL: RESULTS FROM THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) INCEPTION COHORT
DIRECT AND INDIRECT COSTS ASSOCIATED WITH DAMAGE ACCRUAL: RESULTS FROM THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) INCEPTION COHORT Open
O030 / #400 Topic: AS23 - SLE-Diagnosis, Manifestations, & Outcomes ABSTRACT CONCURRENT SESSION 05: EMERGING INSIGHTS ON THE MANAGEMENT OF LUPUS MANIFESTATIONS AND COMORBIDITIES 23-05-2025 1:40 PM - 2:40 PM Background/Purpose We described …
View article: MACHINE LEARNING CAN IDENTIFY AN ANTINUCLEAR ANTIBODY PATTERN THAT MAY RULE OUT SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES
MACHINE LEARNING CAN IDENTIFY AN ANTINUCLEAR ANTIBODY PATTERN THAT MAY RULE OUT SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES Open
O032 / #273 Topic: AS23 - SLE-Diagnosis, Manifestations, & Outcomes ABSTRACT CONCURRENT SESSION 05: EMERGING INSIGHTS ON THE MANAGEMENT OF LUPUS MANIFESTATIONS AND COMORBIDITIES 23-05-2025 1:40 PM - 2:40 PM Background/Purpose Antinuclear a…
View article: Genetic and Epigenetic Dysregulation of CR1 is Associated with Catastrophic Antiphospholipid Syndrome (CAPS)
Genetic and Epigenetic Dysregulation of CR1 is Associated with Catastrophic Antiphospholipid Syndrome (CAPS) Open
Objective Catastrophic antiphospholipid syndrome (CAPS), characterized by widespread thrombosis and multi-organ failure, is associated with high morbidity and mortality. We previously established complement activation as a pathogenic drive…
View article: Direct oral anticoagulants versus Vitamin K antagonists in antiphospholipid syndrome: A systematic review and meta-analysis
Direct oral anticoagulants versus Vitamin K antagonists in antiphospholipid syndrome: A systematic review and meta-analysis Open
This study is registered in PROSPERO (CRD42024582033).
View article: Reply
Reply Open
View article: Second Trimester Kidney Function and Adverse Pregnancy Outcomes among Patients with Lupus
Second Trimester Kidney Function and Adverse Pregnancy Outcomes among Patients with Lupus Open
Key Points In our combined cohort, second trimester kidney function was associated with adverse outcomes for patients with lupus. Measurement of kidney function during pregnancy may have potential benefit, especially among patients without…
View article: Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort
Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort Open
Objective One key target of treating patients with systemic lupus erythematosus (SLE) is to prevent organ damage. This analysis quantified the association between time spent in four specific SLE low disease activity (LDA) states and organ …
View article: Inflammation in Areas of Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis
Inflammation in Areas of Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis Open
Background Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells but typically regarded as nonspecific “scar reaction.” This study aimed to investigate the relationship between inflammatory fibrosis and kidney …
View article: Comparison of cell type and disease subset chromatin modifications in SLE
Comparison of cell type and disease subset chromatin modifications in SLE Open
The pathways identified by altered histone modifications and p300 binding are pathways known to be important from RNA expression studies and recognized pathogenic mechanisms of disease. NFκB and classical inflammatory pathways were strongl…
View article: <scp>SOX</scp>‐5 Transcription Factor: a Novel Psoriatic Autoantigen Preferentially Found in Women
<span>SOX</span>‐5 Transcription Factor: a Novel Psoriatic Autoantigen Preferentially Found in Women Open
Objective Adaptive immunity mediates psoriatic disease pathogenesis. We aimed to identify novel psoriatic autoantigens and their phenotypic associations in deeply characterized patient cohorts. Methods Sera from psoriatic arthritis (PsA) p…
View article: Development of the 2023 <scp>ACR/EULAR</scp> Antiphospholipid Syndrome Classification Criteria, Phase III‐D Report: Multicriteria Decision Analysis
Development of the 2023 <span>ACR/EULAR</span> Antiphospholipid Syndrome Classification Criteria, Phase III‐D Report: Multicriteria Decision Analysis Open
Objective The 2023 American College of Rheumatology/EULAR antiphospholipid syndrome (APS) classification criteria development, which aimed to identify patients with high likelihood of APS for research, employed a four‐phase methodology. Ph…
View article: A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models Open
A defining feature of systemic lupus erythematosus (SLE) is loss of tolerance to self-DNA, and deficiency of DNASE1L3, the main enzyme responsible for chromatin degradation in blood, is also associated with SLE. This association can be fou…